Bellevue Group AG Sells 12,600 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Bellevue Group AG decreased its position in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 27.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 33,551 shares of the medical research company's stock after selling 12,600 shares during the period. Bellevue Group AG owned approximately 0.12% of Bio-Rad Laboratories worth $11,022,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of BIO. Venturi Wealth Management LLC lifted its stake in shares of Bio-Rad Laboratories by 2,175.0% in the fourth quarter. Venturi Wealth Management LLC now owns 91 shares of the medical research company's stock worth $30,000 after buying an additional 87 shares in the last quarter. GeoWealth Management LLC lifted its position in Bio-Rad Laboratories by 342.9% in the 4th quarter. GeoWealth Management LLC now owns 93 shares of the medical research company's stock valued at $31,000 after acquiring an additional 72 shares in the last quarter. Picton Mahoney Asset Management boosted its stake in Bio-Rad Laboratories by 55.6% during the 4th quarter. Picton Mahoney Asset Management now owns 98 shares of the medical research company's stock valued at $32,000 after purchasing an additional 35 shares during the last quarter. Asset Planning Inc bought a new stake in shares of Bio-Rad Laboratories in the 4th quarter worth $33,000. Finally, UMB Bank n.a. increased its holdings in shares of Bio-Rad Laboratories by 41.6% in the 4th quarter. UMB Bank n.a. now owns 109 shares of the medical research company's stock worth $36,000 after purchasing an additional 32 shares in the last quarter. 65.24% of the stock is owned by hedge funds and other institutional investors.

Bio-Rad Laboratories Stock Performance

Shares of NYSE BIO opened at $236.83 on Friday. Bio-Rad Laboratories, Inc. has a 12-month low of $215.38 and a 12-month high of $387.99. The firm has a 50 day moving average of $246.93 and a 200 day moving average of $304.95. The firm has a market capitalization of $6.63 billion, a price-to-earnings ratio of -3.64 and a beta of 1.12. The company has a current ratio of 6.48, a quick ratio of 4.85 and a debt-to-equity ratio of 0.18.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last released its earnings results on Thursday, May 1st. The medical research company reported $2.54 EPS for the quarter, topping analysts' consensus estimates of $1.73 by $0.81. The company had revenue of $585.40 million for the quarter, compared to analysts' expectations of $573.01 million. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.90%. The firm's revenue was down 4.2% compared to the same quarter last year. During the same quarter last year, the business earned $2.30 EPS. On average, research analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current year.

Analyst Ratings Changes

BIO has been the topic of several recent analyst reports. Wells Fargo & Company dropped their price objective on Bio-Rad Laboratories from $320.00 to $270.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 17th. Citigroup reduced their price target on shares of Bio-Rad Laboratories from $400.00 to $350.00 and set a "buy" rating for the company in a research note on Friday. UBS Group lowered their price objective on shares of Bio-Rad Laboratories from $355.00 to $310.00 and set a "buy" rating on the stock in a research report on Friday. StockNews.com downgraded shares of Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research report on Monday, February 17th. Finally, Royal Bank of Canada decreased their target price on shares of Bio-Rad Laboratories from $409.00 to $392.00 and set an "outperform" rating for the company in a research note on Friday. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. According to data from MarketBeat, Bio-Rad Laboratories has a consensus rating of "Moderate Buy" and a consensus target price of $327.40.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.

Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.